Work

Phase 2 study of tarloxotinib bromide (TRLX) in patients (pts) with EGFR-Mutant, T790M-Negative NSCLC progressing on an EGFR TKI.

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.tps9100

Authors: Stephen V. Liu, Charu Aggarwal, Christina Brzezniak, Robert Charles Doebele, David E. Gerber, Barbara Gitlitz, Leora Horn, Benjamin J. Solomon, Tom Stinchcombe, Liza Cosca Villaruz, Howard Jack West, Stew Kroll, Tillman E. Pearce, D. Ross Camidge

Institutions: Georgetown University, University of Pennsylvania, Walter Reed National Military Medical Center, University of Colorado Anschutz, The University of Texas Southwestern Medical Center, University of Southern California, Vanderbilt University Medical Center, Peter MacCallum Cancer Centre, University of North Carolina at Chapel Hill, UPMC Hillman Cancer Center, Threshold Pharmaceuticals (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2487852245

Cites:

Cited by: 11

Related to: 10